EMFLAZA® (deflazacort) is NOW indicated for the treatment of Duchenne muscular dystrophy in patients 2 YEARS OF AGE AND OLDER.

Early intervention may help slow the progression of Duchenne

Due to the progressive nature of the disease, detection and intervention should happen as early as possible. Diagnosis for Duchenne typically happens around 5 years of age and well-established care guidelines make their recommendations for treatment with corticosteroids.

For patients who are considering corticosteroid therapy, the CDC guidelines, developed in collaboration with multiple organizations, recommend that the initiation of corticosteroid therapy must be an individual decision, based on functional state, age, and preexisting risk factors for adverse side effects. The CDC guidelines make the following recommendations regarding the initiation of corticosteroid therapy1,2:

The 3 phases of motor function in DMD (making progress, plateau, and decline) should contribute to the decision-making process

Begin steroid regimen2:
• Before substantial physical decline
• After discussion of side effects
• After nutrition consultation

An intervention of corticosteroids at a later stage is still beneficial to delaying disease progression, extending survival, and maintaining quality of life

It takes a multidisciplinary care team to manage a patient affected by Duchenne2

Duchenne is a complex disease, and patients typically require multidisciplinary care. Depending on the patient’s circumstances, a range of expertise from various disciplines may be needed to carefully manage the disease. Multidisciplinary management of Duchenne patients, in conjunction with corticosteroid therapy, have contributed to slowing the progression of Duchenne. The neuromuscular specialist is a primary component in helping coordinate clinical care among the various disciplines.

multidisciplinary team infographic
Icon of envelope

Register for Updates

1. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77-93. 2. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251-267.